S1PR1 and glioblastoma: Recent studies suggest a complex interplay between CXCR4 and S1P1 signaling in conditions such as multiple myeloma, glioblastoma, and neurodegenerative diseases, where CXCR4 is a primary therapeutic target [99–101].